Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 4/20 | 0.62 |
| ▸ | POLA1 | P09884 | 1/20 | 0.61 |
| ▸ | VDR | P11473 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.55 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16249719 | 0.96 | CDC25A (0.61) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL16249676 | 0.95 | CDC25A (0.60) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL16249677 | 0.95 | CDC25A (0.59) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL16351566 | 0.95 | CDC25A (0.59) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL16351563 | 0.92 | CDC25A (0.65) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL15339526 | 0.92 | CDC25A (0.59) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL15339558 | 0.91 | CDC25A (0.59) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL17124643 | 0.90 | CDC25A (0.61) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL17828421 | 0.90 | CDC25A (0.58) | CDC25APOLA1VDRUSP2CYP2D6 | |
| SCHEMBL16249866 | 0.88 | CDC25A (0.59) | CDC25APOLA1VDRUSP2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378645-A1 | LIQUID CRYSTAL ALIGNING AGENT | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2014-12-25 | — | — | US | disclosed |
| US-20140378645-A1 | LIQUID CRYSTAL ALIGNING AGENT | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2014-12-25 | — | — | US | disclosed |
| EP-2803672-A1 | LIQUID CRYSTAL ALIGNING AGENT | Wako Pure Chemical Industries, Ltd. (JP) | 2014-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378645-A1 | LIQUID CRYSTAL ALIGNING AGENT | CYP17A1, AUP1, NR5A1 | CDC25A 836/4885POLA1 198/4885VDR 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.